Medical  Explorer

Custom Search

Drugs A to Z  :  A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  R  S  T  U  V  W  X  Y  Z
Medicinal Ingredients : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Beauty Products : A  B  C  D  E  F  G  I  M  N  O  P  R  S  T  V

Aging      Allergies     Alzheimer's      Arthritis    Asthma      Bacteria   new Cancer    Chickenpox     Colds     Constipation      Diabetes      Epilepsy     Fatigue     Fever     Genetics       Haemorrhoids       newHeadaches      Hepatitis    Immunity      Infection      Insomnia       Leprosy       Menopause      Obesity      Osteoporosis     Other Diseases    Pain      PMS     Parasites     Sinusitis     newStroke     Toxicology    Urology




Arthritis medications
Acupuncture
Alcohol
Patients
newGeneral Health
Medicinal food
Chinese medicine
Nutrients
Smoking
Vitamins
OTC Drugs
Health Products
Therapy
Symptom
Parasitology
 
 

Cafergot
[ Controlled Medicine ]

Treatment of migraine attacks and related types of vascular headache.

COMPOSITION
Cafergot tablets contain 1 mg ergotamine tartrate and 100 mg caffeine.

 

Pharmaceutical form

Tablets.

Description
Circular, flat, bevelled edge tablet of speckled yellowish/whitish colour, scored and coded "XU on one side.

INDICATIONS
Acute attacks of migraine (classical migraine) and related types of vascular headache.

DOSAGE AND ADMINISTRATION
Cafergot should be given at the first symptoms of an attack.

Adults
The first time Cafergot is taken, an initial dose of 2 Cafergot tablets orally is recommended. If relief is not obtained within half an hour, a further tablet should be administered; this may be repeated at half-hourly intervals, but the maximum daily dose indicated below should not be exceeded.

For subsequent attacks the initial dose may be increased to 3 tablets, depending on the total dose required in previous attacks. If pain persists, additional doses of 1 tablet may be taken at half-hourly intervals up to the maximum dose (see below).

The following restriction must be observed:
If supplementary antimigraine medication is required, the use of any ergotamine-containing preparations, intranasal or parenteral dihydroergotamine or sumatriptan or other 5HT1-receptor agonists must be avoided (see section "CONTRAINDICATIONS").

Maximum dose per attack or per day
Adults: 6 mg ergotamine tartrate = 6 tablets.

Maximum weekly dose
Adults: 10 mg ergotamine tartrate = 10 tablets

CONTRAINDICATIONS
Known hypersensitivity to ergot alkaloids, caffeine, or any other components of the formulations (see section "EXCIPIENTS").

Pregnancy and breast-feeding (see section "PREGNANCY AND LACTATION")

Impaired peripheral circulation, obliterative vascular disease, coronary heart disease, inadequately controlled hypertension, septic conditions, shock.

Severe renal or hepatic impairment.

Temporal arteritis.

Hemiplegic or basilar migraine.

Concomitant treatment with macrolide antibiotics, HIV protease or reverse transcriptase inhibitors, azole antifungals (see section "INTERACTIONS").

Concomitant treatment with vasoconstrictor agents (including ergot alkaloids, sumatriptan and other 5HT1 receptor agonists) (see section "INTERACTIONS").

SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Cafergot is only indicated for the treatment of acute migraine attacks and not for prevention.

Continued daily use of Cafergot or it's use in excess of the recommended doses must be avoided since it may cause vasospasm.

If contrary to recommendations (see section "SPECIAL WARNINGS AND PRECAUTIONS FOR USE") ergotaminecontaining drugs including Cafergot are used excessively over years, they may induce fibrotic changes, in particular of the pleura and the retroperitoneum. There have also been rare reports of fibrotic changes of the cardiac valves.

Patients who are being treated with Cafergot should be informed of the maximum doses allowed and of the first symptoms of overdosage: paresthesia (e.g. numbness, tingling) in the fingers and toes, non-migraine-related nausea and vomiting, and symptoms of myocardial ischaemia (e.g. precordial pain). If symptoms such as tingling in the fingers or toes occur, the drug should be discontinued at once and the physician consulted.

Patients with mild to moderate hepatic impairment, especially cholestatic patients should be appropriately monitored.

The occurrence of drug-induced headaches has been reported during prolonged and uninterrupted treatment with Cafergot.

Rare cases of a solitary rectal or anal ulcer have occurred from abuse of ergotamine-containing suppositories, usually at higher than recommended doses or with continuous use at the recommended dose for many years.

INTERACTIONS
The concomitant use of cytochrome P450 3A (CYP3A) inhibitors such as macrolide antibiotics (e.g. troleandomycin, erythromycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g. ritonavir, indinavir, nelfinavir, delavirdine or azole antifungals (e.g. ketoconazole, itraconazole, voriconazole) and Cafergot must be avoided (see section "CONTRAINDICATIONS"), since this can result in an elevated exposure to ergotamine and ergot toxicity (vasospasm and ischemia of the extremities and other tissues). Ergot alkaloids have also been shown to be inhibitors of CYP3A. No pharmacokinetic interactions involving other cytochrome P450 isoenzymes are known.

A few cases of vasospastic reactions have been reported among patients treated concomitantly with ergotamine-containing preparations and propranolol.

Concurrent use of vasoconstrictor agents including preparations containing ergot alkaloids, sumatriptan and other 5HT1 receptor agonists, and nicotine (e.g. heavy smoking) must be avoided since this may result in enhanced vasoconstriction (see "CONTRAINDICATIONS")

1    2

Abdomen
Blood
Bone
Breast
Ear

Eye

Face
Hair

Head

Heart
Kidney
Liver
Limbs
Lungs
newMind
Mouth
Muscles
Nails

Neck

newNerves
Nose

Skin

Teeth

Throat

Tongue
 
Health news
 
Cardiovascular Guide
 
Natural Remedies
 
Treatment of Cancer
 
Women's Health
 
Irritable bowel syndrome
 
Common Childhood Illnesses
 
Prescribed Drugs
 
 

     
         
     

 

Disclaimer